Login
$ORIC
$7.52 -$0.34 (4.33%) Live

$ORIC 8-K SEC Filings

Filed On Filing
23 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including stateme...

03 Aug 2026 8-K: Results of Operations and Financial Condition

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone

30 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Co...

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

to attract and retain the best available personnel for positions of substantial responsibility,

04 May 2026 8-K: Results of Operations and Financial Condition

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026

31 Mar 2026 8-K: Other Events

Exhibit 99.1 Rinzimetostat Dose Optimization Data Update March 31, 2026

23 Feb 2026 8-K: Other Events

We have acted as counsel to ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the registration of the proposed offer and sale of up to $200,000,000 of shares (the “Shares”) of the Company’s common sto...

23 Feb 2026 8-K: Results of Operations and Financial Condition

Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors

08 Dec 2025 8-K: Other Events

Exhibit 99.1 Enozertinib (ORIC-114) Program Update December 6, 2025

13 Nov 2025 8-K: Regulation FD Disclosure

ORIC-944 Dose Exploration Data Update November 13, 2025 Exhibit 99.1

13 Nov 2025 8-K: Results of Operations and Financial Condition

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety

12 Aug 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC

13 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2025, ORIC Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders. Of the 71,085,080 shares of common stock outstanding as of April 16, 2025, the record date for the meeting, 58,306,933 shares of common...

28 May 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This Securities Purchase Agreement (the “Agreement”) is made as of May 23, 2025 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set...

05 May 2025 8-K: Results of Operations and Financial Condition

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones

14 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Co...

25 Feb 2025 8-K: Other Events

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

18 Feb 2025 8-K: Results of Operations and Financial Condition

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC

13 Jan 2025 8-K: Regulation FD Disclosure

Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including stateme...

12 Nov 2024 8-K: Results of Operations and Financial Condition

Presented preclinical data further supporting the potential best-in-class profile of

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support